FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383559186> ?p ?o ?g. }

• W4383559186 abstract "Abstract Background S-1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) are standard first-line regimens for advanced gastric cancer (AGC) worldwide. We conducted a meta-analysis using individual participant data (IPD) to investigate which is more suitable. Methods IPD from three randomized trials were collected. In these trials, patients with AGC were randomly allocated to SP (S-1 80–120 mg for 21 days plus cisplatin 60 mg/m 2 (q5w)) or XP (capecitabine 2,000 mg/m 2 for 14 days plus cisplatin 80 mg/m 2 (q3w)). Results In 211 eligible patients, median overall survival (OS) for SP versus XP was 13.5 and 11.7 months (hazard ratio [HR], 0.787; p = 0.114), progression-free survival (PFS) was 6.2 and 5.1 months (HR, 0.767; P = 0.076), and TTF was 5.1 and 4.0 months (HR, 0.611; P = 0.001). The most common grade ≥ 3 adverse events with SP or XP were neutropenia (18% vs. 29%) and anorexia (16% vs. 18%). Subgroup analysis demonstrated significant interaction between treatment effect and performance status > 1 (HR, 0.685; P = 0.036), measurable lesion (HR, 0.709; P = 0.049), primary upper third tumor (HR, 0.539; P = 0.040), and differentiated type (HR, 0.549; interaction, 0.236; P = 0.019). For the differentiated type, OS was significantly longer in the SP group (13.2 months) than in the XP group (11.1 months) (HR, 0.549; P = 0.019). For the undifferentiated type, OS was similar in the SP group (14.2 months) and in the XP group (12.4 months) (HR, 0.868; P = 0.476). Conclusions SP and XP were both effective and well tolerated. SP might be suitable for the pathological differentiated subtype of AGC." @default.
• W4383559186 created "2023-07-08" @default.
• W4383559186 creator A5007258796 @default.
• W4383559186 creator A5014764058 @default.
• W4383559186 creator A5031710130 @default.
• W4383559186 creator A5038751838 @default.
• W4383559186 creator A5040552693 @default.
• W4383559186 creator A5043504350 @default.
• W4383559186 creator A5049222956 @default.
• W4383559186 creator A5058441704 @default.
• W4383559186 creator A5058524907 @default.
• W4383559186 creator A5060716896 @default.
• W4383559186 creator A5065342574 @default.
• W4383559186 creator A5067567361 @default.
• W4383559186 creator A5073926001 @default.
• W4383559186 date "2023-07-07" @default.
• W4383559186 modified "2023-10-06" @default.
• W4383559186 title "Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer" @default.
• W4383559186 cites W1994843088 @default.
• W4383559186 cites W2022609714 @default.
• W4383559186 cites W2050118439 @default.
• W4383559186 cites W2077902459 @default.
• W4383559186 cites W2099756738 @default.
• W4383559186 cites W2100439220 @default.
• W4383559186 cites W2116880983 @default.
• W4383559186 cites W2122866527 @default.
• W4383559186 cites W2125062521 @default.
• W4383559186 cites W2126547130 @default.
• W4383559186 cites W2127773543 @default.
• W4383559186 cites W2128328462 @default.
• W4383559186 cites W2131972171 @default.
• W4383559186 cites W2145390243 @default.
• W4383559186 cites W2152362765 @default.
• W4383559186 cites W2155167083 @default.
• W4383559186 cites W2171075804 @default.
• W4383559186 cites W2238191161 @default.
• W4383559186 cites W2604423605 @default.
• W4383559186 cites W2751124093 @default.
• W4383559186 cites W2768775725 @default.
• W4383559186 cites W2887620950 @default.
• W4383559186 cites W2904895170 @default.
• W4383559186 cites W2906436263 @default.
• W4383559186 cites W3018126413 @default.
• W4383559186 cites W3030046145 @default.
• W4383559186 cites W3128646645 @default.
• W4383559186 cites W3171517418 @default.
• W4383559186 cites W4206384216 @default.
• W4383559186 cites W4309737608 @default.
• W4383559186 doi "https://doi.org/10.21203/rs.3.rs-3109064/v1" @default.
• W4383559186 hasPublicationYear "2023" @default.
• W4383559186 type Work @default.
• W4383559186 citedByCount "0" @default.
• W4383559186 crossrefType "posted-content" @default.
• W4383559186 hasAuthorship W4383559186A5007258796 @default.
• W4383559186 hasAuthorship W4383559186A5014764058 @default.
• W4383559186 hasAuthorship W4383559186A5031710130 @default.
• W4383559186 hasAuthorship W4383559186A5038751838 @default.
• W4383559186 hasAuthorship W4383559186A5040552693 @default.
• W4383559186 hasAuthorship W4383559186A5043504350 @default.
• W4383559186 hasAuthorship W4383559186A5049222956 @default.
• W4383559186 hasAuthorship W4383559186A5058441704 @default.
• W4383559186 hasAuthorship W4383559186A5058524907 @default.
• W4383559186 hasAuthorship W4383559186A5060716896 @default.
• W4383559186 hasAuthorship W4383559186A5065342574 @default.
• W4383559186 hasAuthorship W4383559186A5067567361 @default.
• W4383559186 hasAuthorship W4383559186A5073926001 @default.
• W4383559186 hasBestOaLocation W43835591861 @default.
• W4383559186 hasConcept C121608353 @default.
• W4383559186 hasConcept C126322002 @default.
• W4383559186 hasConcept C168563851 @default.
• W4383559186 hasConcept C187960798 @default.
• W4383559186 hasConcept C197934379 @default.
• W4383559186 hasConcept C207103383 @default.
• W4383559186 hasConcept C2776694085 @default.
• W4383559186 hasConcept C2777063308 @default.
• W4383559186 hasConcept C2777909004 @default.
• W4383559186 hasConcept C2778239845 @default.
• W4383559186 hasConcept C44249647 @default.
• W4383559186 hasConcept C526805850 @default.
• W4383559186 hasConcept C71924100 @default.
• W4383559186 hasConcept C90924648 @default.
• W4383559186 hasConceptScore W4383559186C121608353 @default.
• W4383559186 hasConceptScore W4383559186C126322002 @default.
• W4383559186 hasConceptScore W4383559186C168563851 @default.
• W4383559186 hasConceptScore W4383559186C187960798 @default.
• W4383559186 hasConceptScore W4383559186C197934379 @default.
• W4383559186 hasConceptScore W4383559186C207103383 @default.
• W4383559186 hasConceptScore W4383559186C2776694085 @default.
• W4383559186 hasConceptScore W4383559186C2777063308 @default.
• W4383559186 hasConceptScore W4383559186C2777909004 @default.
• W4383559186 hasConceptScore W4383559186C2778239845 @default.
• W4383559186 hasConceptScore W4383559186C44249647 @default.
• W4383559186 hasConceptScore W4383559186C526805850 @default.
• W4383559186 hasConceptScore W4383559186C71924100 @default.
• W4383559186 hasConceptScore W4383559186C90924648 @default.
• W4383559186 hasLocation W43835591861 @default.
• W4383559186 hasOpenAccess W4383559186 @default.
• W4383559186 hasPrimaryLocation W43835591861 @default.
• W4383559186 hasRelatedWork W2194631636 @default.
• W4383559186 hasRelatedWork W2300511943 @default.

• next